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Abstract 
We describe a case of progressive multifocal leukoencephalopathy (PML) caused by 
infection with the human polyomavirus JC virus in a patient with B-cell small 
lymphocytic leukemia who was treated with rituximab. The first symptoms of PML 
appeared immediately following the last of five cycles of rituximab, cyclophosphamide 
and pentostatin. Magnetic resonance imaging revealed changes consistent with PML, 
although JC virus DNA was not detected by polymerase chain reaction assay of the 
cerebrospinal fluid. A stereotactic biopsy of the brain showed histological changes 
consistent with PML, while electron microscopy revealed JC virus particles attached to 
the nuclei of astrocytes. The patient was treated supportively but died 53 days after the 
initial onset of symptoms.  
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Background 
Rituximab is a chimeric human/mouse IgG1-κ monoclonal antibody that targets the 
CD20 antigen expressed on the surface of both normal and malignant B lymphocytes. The 
CD20 antigen, while being expressed in nearly 90% of B-cell non-Hodgkin lymphomas 
(NHLs) and a smaller proportion of B-cell chronic lymphocytic leukemia (CLL) cells, is 
not expressed by hematopoietic stem cells. As a result, treatment with rituximab is 
associated with an initial decrease in lymphocyte count which recovers 9–12 months 
following completion of the therapy [1]. Rituximab is currently approved for the 
treatment of CD20-positive hematologic malignancies (NHLs and CLL) and as 
maintenance therapy for follicular lymphoma and other indolent B-cell malignancies. 
Rituximab has also been employed for the treatment of non-malignant autoimmune 
disorders, chiefly rheumatoid arthritis and systemic lupus erythematosus (SLE) [2]. 
Progressive multifocal leukoencephalopathy (PML) is a lethal, progressive 
demyelinating disorder of the central nervous system (CNS) characterized by the 
destruction of oligodendrocytes due to the reactivation of a type of human polyoma virus 
called the John Cunningham (JC) virus [3]. Interestingly, while 50–86% of healthy adults 
are seropositive for JC virus, reactivation of the virus occurs almost exclusively in patients 
with an impaired cellular immune response (nearly 85% cases of PML occur in human 
immunodeficiency virus (HIV)-positive patients) [4]. Although the virus ultimately 
lodges in and damages the CNS, its journey begins by binding to and entering the 
B-lymphocytes by a clathrin-dependent pathway. Most of the virions however do not 
enter the B-cells to establish infection, remaining attached instead to their surface. The 
infected B-lymphocytes enter the CNS through the blood flow, carrying the virus with 
them. Once in the CNS, the virus infects astrocytes and oligodendrocytes. Infection of the 
latter causes a massive demyelination in the CNS leading to focal neurological deficits, the 
hallmark of PML. The disease has a rapid clinical course with an extremely poor clinical 
outcome, the overall median survival without treatment being a mere 3.5 months [3]. 
In 2006, following the report of two patients with SLE who developed PML following 
rituximab treatment, the Food and Drug Administration issued an alert concerning the 
use of rituximab in SLE [2]. A review of literature published recently [5] revealed that 
57 cases of rituximab-associated PML were reported to date, most in patients who had 
lymphoproliferative disorders. We describe the development of PML in a patient with 
B-cell CLL who had received rituximab as part of a combination therapy with pentostatin 
and cyclophosphamide. 
Case Report 
A 70-year-old man with stage IV B-cell small lymphocytic leukemia (SLL) presented to the hospital 
with complaints of confusion, memory loss and loss of vision. He had recently (2 weeks prior to onset of 
symptoms) completed five cycles of chemotherapy with rituximab, pentostatin and cyclophosphamide 
for progressive SLL (achieved nearly complete response as assessed by approximately 90% reduction in 
cervical, submandibular and axillary adenopathy). The patient had been in good health during his 
chemotherapy except for mild treatment-associated anemia and an episode of herpes zoster (on the left 
shoulder) after the fourth cycle which resolved completely with valacyclovir. His wife reported that two 
weeks back she had noticed that he appeared confused and took longer than usual to respond to her 
questions or suggestions. Around this time, the patient had also noticed a subjective decrease in vision 
(in both eyes) which had become progressively worse over the last two weeks. There was no history of 
trauma, seizures or stroke.   
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A neurologic examination revealed that he was oriented to person, generally to place but not to 
time. Objective ophthalmologic examination revealed significantly decreased vision in all planes 
bilaterally. Other significant findings included difficulty with upward gaze, reduced vibration sense 
bilaterally in the lower extremities and a positive Babinski response. An magnetic resonance imaging 
(MRI) scan with T2-weighting and fluid-attenuated inversion recovery (fig. 1) obtained at presentation 
revealed a hyperintense lesion in the deep white matter of the left temporal lobe and several 
hyperintense lesions in the subcortical, deep and periventricular white matter of the parieto-occipital 
region bilaterally. The lesions were mainly confined to the white matter with relative sparing of the 
cortex. No enhancement was observed following administration of gadolinium. There were no signs 
of a mass effect or midline shift. The white matter changes were thought to be consistent with either 
PML or posterior reversible encephalopathy syndrome. Laboratory investigations were significant for 
leukopenia (total WBC count 2,400/μl, reference range: 4,000–11,000/μl), anemia (hemoglobin 
11.6 g/dl, reference range: 13.0–18.0 g/dl), thrombocytopenia (platelet count 105,000/μl, reference 
range: 150,000–400,000/μl) and decreased serum IgG (591 mg/dl, reference range: 768–1,632 mg/dl). 
Cerebrospinal fluid analysis revealed presence of erythrocytes (32/μl, reference range: 0/μl), elevated 
total protein (73 mg/dl, reference range: 15–45 mg/dl) and a decreased IgG to albumin ratio (0.06, 
reference range: 0.09–0.25). Polymerase chain reaction for cytomegalovirus and JC virus DNA was 
negative. 
Over the next five days, the patient’s symptoms progressively worsened with psychomotor slowing, 
appearance of abnormal eye movements and psychotic episodes together with persistence of his earlier 
subjective visual impairment. Laboratory studies at this time revealed persistence of the hematological 
changes with a further drop in the platelet count (97,000/μl). Tests for anti-thyroid peroxidase 
antibodies and anti-thyroglobulin antibodies and assays for syphilis, HIV-1 and HIV-2, IgG and IgM 
antibodies to Borrelia burgdorferi were negative.  
An MRI scan of the brain revealed a slight increase in the size of the lesions in the parieto-occipital 
regions although no new lesions were noticed (fig. 2). A week later (3rd week post-admission), a 
stereotactic biopsy of the right parietal lobe was performed. Hematoxylin and eosin staining (fig. 3) 
revealed diffuse astrocytosis with many of the astrocytes containing large, irregular nuclei. Occasionally, 
a smudgy material was observed within their nuclei. Oligodendroglial cells were sparse, enlarged and 
contained ground glass inclusions. Conventional electron microscopy images of astrocytes in the same 
sections revealed presence of enlarged and irregular nuclei. The nuclei exhibited focal loss of nuclear 
envelope with viral particles attached to the nuclear envelope in clusters. Higher magnification revealed 
numerous icosahedral 35–45 nm viral particles within the astrocyte nucleus consistent with a 
papovavirus, specifically JC virus. Following diagnosis, the patient was counseled regarding possible 
treatment options including cidofovir therapy. However, the patient decided against treatment and died 
53 days after the initial onset of his symptoms. 
Discussion 
PML is a lethal, progressive demyelinating disorder of the CNS characterized by 
destruction of oligodendrocytes due to the reactivation of a type of human polyoma virus 
called the JC virus [3]. While 50–86% of healthy adults are seropositive for the virus, 
reactivation occurs almost exclusively in patients with an impaired cellular immune 
response (nearly 85% of PML cases occur in HIV-positive patients) [4]. The disease has a 
rapid clinical course with an extremely poor clinical outcome, the overall median survival 
without treatment being a mere 3.5 months [3]. Rituximab is a chimeric human/mouse 
IgG1-κ monoclonal antibody that targets the CD20 antigen expressed on the surface of 
both normal and malignant B lymphocytes (both in NHLs and CLL). It is currently 
approved for the treatment of CD20-positive hematologic malignancies (NHLs and CLL) 
and as maintenance therapy for follicular lymphoma and other indolent B-cell 
malignancies. Rituximab has also been employed for the treatment of non-malignant 
autoimmune disorders, chiefly rheumatoid arthritis and SLE [2]. In 2006, following the 
report of two patients with SLE who developed PML after rituximab treatment, the Food  
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and Drug Administration issued an alert concerning the use of rituximab in SLE [2]. A 
review of literature published recently [5] revealed that 57 cases of rituximab-associated 
PML were reported to date, most in patients who had lymphoproliferative disorders. A 
few cases have also been observed in patients treated for other immune-mediated illnesses 
including SLE, rheumatoid arthritis, idiopathic autoimmune pancytopenia and immune 
mediated thrombocytopenia. The disease appears to set in relatively early in affected 
patients following the start of rituximab therapy (median time of onset from the last dose 
being about 6 months), progresses rapidly (median time to death following diagnosis 
about 2 months) and is nearly always fatal. Factors predicting a rapid progression of the 
disease include a CD4+ lymphocyte count <500 cells/μl and diagnosis of PML within 
3 months following start of rituximab therapy. Nearly all patients who survive suffer from 
residual neurologic deficits including hemiparesis, motor aphasia and visual defects. The 
treatment of PML is mostly supportive and removal of the offending drug (rituximab) is a 
key part of the therapeutic regimen. Plasma exchange to remove the drug has also been 
shown to be helpful in treatment and possibly works by restoring the immune function of 
the CNS [6]. A comparison of our patient with other reported cases revealed several 
unique characteristics. The most striking feature was the extremely short duration 
between the last dose of rituximab and the first onset of symptoms (1–2 days). The lowest 
interval reported so far is 9 days [5]. It has been suggested that a combination of a low 
CD4+ count and low serum IgG levels is associated with a syndrome of rapid activation of 
the JC virus following rituximab administration [5, 7]. Although a CD4+ count (at the 
time of diagnosis) was not available in our case, the patient did have an episode of zoster 
after the fourth cycle of chemotherapy, suggestive of a decrease in cell-mediated 
immunity. Further, he had a low serum IgG at presentation. We hypothesize that a 
combination of decreased cellular and humoral immune response prompted a 
reactivation of the dormant virus in this patient. Further, the patient had not received 
prior stem cell transplant, and presented with significant and rapidly progressing loss of 
vision, a relatively uncommon symptom reported by only 18% of non-transplanted and 
13% of post-transplant patients with post-rituximab PML [6]. A second observation was 
the presence of JC virus particles in astrocytes, a unique finding as the virus typically 
infects oligodendrocytes although both glial cells and astrocytes express the receptor for 
JC virus (5-hydroxytryptamine receptor 2A) [8]. 
The present case represents a rare but deadly complication of rituximab therapy in SLL 
patients. A deciphering of the molecular mechanisms underlying JC virus infection will 
potentially permit a better understanding of the pathogenesis of JC virus-associated PML 
and could possibly lead to the development of novel targeted therapeutic approaches in 
the future. 
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Fig. 1. An MRI scan with T2-weighting and with fluid-attenuated inversion recovery (a–c) obtained 
at the time of initial presentation shows a hyperintense lesion in the deep white matter of the left 
temporal lobe (a) and several lesions in the subcortical, deep and periventricular white matter of the 
parieto-occipital region bilaterally (b, c). These lesions were mainly confined to the white matter as 
shown by the relative sparing of the cortex and were not enhanced by the administration of gadolinium 
on T1-weighted MRI (d–f). Arrowheads: hypointense lesions corresponding to the lesions in a, b and 
c, respectively.  
 
 
 
Fig. 2. Follow-up MRI scan two weeks after initial presentation revealed a slight increase in size of 
lesions in the parieto-occipital region (comparison with fig. 1). However, no new lesions were noted 
anywhere. A gadolinium-enhanced T1-weighted MRI revealed that the non-enhancing lesions were 
better delineated (d–f). Arrowheads: hypointense lesions corresponding to the lesions in a, b and c, 
respectively.  
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Fig. 3. Histologic and electron microscopic findings of PML. Hematoxylin and eosin-stained section of 
the right parietal lobe (a, b) showing shows diffuse astrocytosis (a, original magnification ×200) with 
many of the astrocytes containing large, irregular nuclei (arrows). Occasionally, a smudgy type of 
material was observed within their nuclei (inset shows a magnified view of astrocytes with enlarged 
nuclei, original magnification ×400). Oligodendroglial cells were sparse and enlarged and contained 
ground glass inclusions (b, arrows, original magnification ×200) (inset shows the magnified image of 
an oligodendrocyte with viral inclusion body in the nucleus, original magnification ×400). 
Conventional electron microscopy images of astrocytes from a stereotactic biopsy of the right parietal 
lobe showing enlarged and irregular nuclei (c, original magnification ×8,000, and d, original 
magnification ×15,000). The nuclei exhibit focal loss of nuclear envelope (NE) (arrowheads) while viral 
particles are observed attached to the nuclear membrane in clusters (e, original magnification 
×60,000). Higher magnification reveals numerous icosahedral 35–45 nm viral particles within the 
astrocyte nucleus (f, original magnification ×300,000). C = Cytoplasm; N = nucleus; NE = nuclear 
envelope. 
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